90%Confidence
0Views
FDASource
2026-04-07Date
Summary
Another Class II recall for Teva's Octreotide Acetate (10mg) reinforces systemic sterility problems at the same Greek contract manufacturer, signaling broader quality failures. This recurring issue may necessitate supply chain restructuring and could trigger regulatory penalties or litigation risks.
Actionable: Investigate Teva's contingency plans for alternative manufacturing to mitigate ongoing recall risks.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now